Mara Penne1, Maryam Sarraf Yazdy1, Kruti Sheth Nair1, Bruce D Cheson2. 1. Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC. 2. Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC. Electronic address: bdc4@georgetown.edu.
Abstract
INTRODUCTION: Bendamustine, typically in combination with rituximab, is an effective treatment for chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin lymphoma. Despite its acceptable short-term toxicity profile, long-term toxicities are less well established. This study investigated the long-term adverse effects of bendamustine and responses to subsequent treatments. PATIENTS AND METHODS: Charts of 194 patients were retrospectively reviewed; 54% had received prior treatment (76% attained complete response [CR] or partial response [PR]). RESULTS: Patients who did not achieve a CR or PR did not respond well to subsequent treatments. Malignancies following bendamustine were diagnosed in 11% (21) of patients (first line [7] and salvage [14]), including squamous (8) or basal cell (4) skin cancers; prostate cancer (3), renal cancer (3), bladder cancer (2), melanoma (2), lung cancer (1), and histiocytic sarcoma (1). There were no occurrences of therapy-related myelodysplastic syndrome or acute myelogenous leukemia reported. Infections occurred in 63% of patients; however, no deaths were attributable to bendamustine. CONCLUSION: Bendamustine is an effective therapy with limited long-term sequelae in patients with lymphoid malignancies.
INTRODUCTION:Bendamustine, typically in combination with rituximab, is an effective treatment for chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin lymphoma. Despite its acceptable short-term toxicity profile, long-term toxicities are less well established. This study investigated the long-term adverse effects of bendamustine and responses to subsequent treatments. PATIENTS AND METHODS: Charts of 194 patients were retrospectively reviewed; 54% had received prior treatment (76% attained complete response [CR] or partial response [PR]). RESULTS:Patients who did not achieve a CR or PR did not respond well to subsequent treatments. Malignancies following bendamustine were diagnosed in 11% (21) of patients (first line [7] and salvage [14]), including squamous (8) or basal cell (4) skin cancers; prostate cancer (3), renal cancer (3), bladder cancer (2), melanoma (2), lung cancer (1), and histiocytic sarcoma (1). There were no occurrences of therapy-related myelodysplastic syndrome or acute myelogenous leukemia reported. Infections occurred in 63% of patients; however, no deaths were attributable to bendamustine. CONCLUSION:Bendamustine is an effective therapy with limited long-term sequelae in patients with lymphoid malignancies.
Authors: Ana Cordeiro; Evandro D Bezerra; Alexandre V Hirayama; Joshua A Hill; Qian V Wu; Jenna Voutsinas; Mohamed L Sorror; Cameron J Turtle; David G Maloney; Merav Bar Journal: Biol Blood Marrow Transplant Date: 2019-08-13 Impact factor: 5.742
Authors: Christopher J Forlenza; Nitya Gulati; Audrey Mauguen; Michael J Absalon; Sharon M Castellino; Anna Franklin; Frank G Keller; Neerav Shukla Journal: Blood Adv Date: 2021-12-28
Authors: Juan Pablo Alderuccio; Luca Arcaini; Marcus P Watkins; Anne W Beaven; Geoffrey Shouse; Narendranath Epperla; Michele Spina; Alexandra Stefanovic; Jose Sandoval-Sus; Pallawi Torka; Ash B Alpert; Adam J Olszewski; Seo-Hyun Kim; Brian Hess; Sameh Gaballa; Sabarish Ayyappan; Jorge J Castillo; Lisa Argnani; Timothy J Voorhees; Raya Saba; Sayan Mullick Chowdhury; Fernando Vargas; Isildinha M Reis; Deukwoo Kwon; Jonathan S Alexander; Wei Zhao; Dali Edwards; Peter Martin; Emanuele Cencini; Manali Kamdar; Brian K Link; Constantine N Logothetis; Alex F Herrera; Jonathan W Friedberg; Brad S Kahl; Stefano Luminari; Pier Luigi Zinzani; Izidore S Lossos Journal: Blood Adv Date: 2022-04-12